Evidence map›Paper›PMID 41494455›Full record

ArticleMolecular pharmacology2026

Elucidating molecular mechanisms governing tumor necrosis factor-alpha-mediated regulation of amyloid beta 42 uptake in blood-brain barrier endothelial cells.

Vrishali S Salian, Geoffry L Curan, Val J Lowe, Xiaojia Tang, Krishna R Kalari, Karunya K Kandimalla

Abstract read
In one paragraph

Article in Molecular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Vrishali S SalianDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.
Geoffry L CuranDepartment of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Val J LoweDepartment of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Xiaojia TangDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Krishna R KalariDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Karunya K KandimallaDepartment of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota. Electronic address: kkandima@umn.edu.

Funding

Amyloid beta peptides and type-2 diabetes sequelae synergistically inhibit insulin signaling and trafficking at the blood brain barrierR01NS125437 · NINDS · UNIVERSITY OF MINNESOTA · PI KARUNYA KUMAR KANDIMALLA, VAL JOHN LOWE · 2022 to 2026
$2.6M
CRCNS: Deep Learning to Discover Neurovascular Disruptions in Alzheimer's DiseaseR01AG085900 · NIA · UNIVERSITY OF MINNESOTA · PI Carlos Fernandez-Granda, Mikel Hernaez · 2023 to 2026
$1.2M
NIA NIH HHS R01 AG085900NINDS NIH HHS R01 NS125437
6 · The paper itself

Abstract

Cerebrovascular inflammation is prevalent in a majority of patients with Alzheimer disease. Elevated levels of inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), circulating in the plasma have been shown to cause the inflammation of blood-brain barrier (BBB) endothelium lining the cerebral microvasculature in Alzheimer disease. The BBB inflammation triggered by exposure of TNF-α in the peripheral circulation can aggravate the accumulation of Aβ peptides in Alzheimer disease brain. In the current study, we have shown that infusion of wild-type mice with TNF-α led to an increase in permeability and influx of Aβ42 into the mice brain using dynamic single-photon emission computed tomography/computed tomography imaging. To corroborate these findings, we demonstrated that TNF-α increases Aβ42 accumulation in vitro in human cerebral microvascular endothelial cells /D3 and primary porcine brain endothelial cells. In addition, our results in human cerebral microvascular endothelial cells/D3 polarized monolayers show that TNF-α alters the expression of cofilin, actin, and dynamin, which are critical components for Aβ endocytosis by BBB endothelial cells. These results suggest a mechanistic pathway by which TNF-α may promote Aβ accumulation at the BBB and the underlying interactions between inflammation and Aβ exposure that drives BBB dysfunction. Hence, a therapeutic intervention aimed at addressing elevated TNF-α levels in Alzheimer disease may potentially reduce Aβ-related cerebrovascular dysfunction in Alzheimer disease brain. SIGNIFICANCE STATEMENT: Elevated plasma tumor necrosis factor-α drives Aβ pathology in Alzheimer disease, promoting cerebrovascular inflammation, but its role in endothelial Aβ uptake in the brain is unclear. This study shows tumor necrosis factor-α increases Aβ42 accumulation in the blood-brain barrier endothelium by altering the expression of blood-brain barrier endocytic proteins cofilin, actin, and dynamin.

Indexed as

Amyloid beta-PeptidesBlood-Brain BarrierEndothelial CellsPeptide FragmentsTumor Necrosis Factor-alphaAlzheimer DiseaseAnimalsBrainCells, CulturedEndocytosisHumansMaleMiceMice, Inbred C57BLSwineAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide FragmentsTumor Necrosis Factor-alphaAlzheimer diseaseAβ42Blood-brain barrierTumor necrosis factor-α

Identifiers

PMID41494455
PMCPMC13095448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.